Misplaced Pages

Methaniazide

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Methaniazide
Clinical data
Trade namesErbazid, Neoiscotin, Neo-Iscotin, Nesticide, Neotizide, Neo-Tizide
Other namesMetaniazide; Neotizide; Isoniazid methanesulfonate; Isoniazid methanosulfonate; Isoniazid mesylate; Isonicotinic acid hydrazide methanesulfonate
Identifiers
IUPAC name
  • methanesulfonic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.033.264 Edit this at Wikidata
Chemical and physical data
FormulaC7H9N3O4S
Molar mass231.23 g·mol
3D model (JSmol)
SMILES
  • C1=CN=CC=C1C(=O)NNCS(=O)(=O)O
InChI
  • InChI=1S/C7H9N3O4S/c11-7(6-1-3-8-4-2-6)10-9-5-15(12,13)14/h1-4,9H,5H2,(H,10,11)(H,12,13,14)
  • Key:GQZQCROBCYNTMU-UHFFFAOYSA-N

Methaniazide, brand name Neotizide among others, is an antibiotic which was used in the treatment of tuberculosis. It is a derivative of methanesulfonic acid and isoniazid, which is also an antituberculosis drug but has comparatively been far more widely known and used. Isoniazid is a prodrug of isonicotinic acid, and acetylisoniazid, a metabolite of isoniazid, is a metabolic intermediate through which most of the isonicotinic acid is formed. Methaniazide features its mesylate group at the same position as that of the acetyl group in acetylisoniazid, and so methaniazide probably acts as a prodrug of isonicotinic acid similarly to isoniazid and acetylisoniazid. Methaniazide is used as the sodium salt. It was never approved for use or sale in the United States.

Neothetazone is an antibiotic combination of methaniazide (neotizide) and thioacetazone which was previously used in the treatment of tuberculosis. It has been associated with a case report of gigantomastia. Similarly, there have been a variety of case reports in the literature of gynecomastia associated with isoniazid treatment.

References

  1. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 709–. ISBN 978-1-4757-2085-3.
  2. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 177–. ISBN 978-94-011-4439-1.
  3. "Methaniazide". Drugs.com. Archived from the original on 2019-08-08. Retrieved 2017-06-24.
  4. Testa B, Mayer JM (August 2003). "The Hydrolysis of Amides". Hydrolysis in Drug and Prodrug Metabolism. John Wiley & Sons. pp. 149–. doi:10.1002/9783906390444.ch4. ISBN 978-3-906390-25-3.
  5. "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Retrieved 2022-08-11.
  6. ^ SAMJ. Medical Association of South Africa. 1970. pp. 449–450. Diffuse hypertrophy of the breasts seems to have been associated in this patient with treatment with Neothetazone, which consists of neotizide and thiacetazone, and which is very commonly used in the treatment of tuberculosis.
  7. Sakai Y, Wakamatsu S, Ono K, Kumagai N (August 2002). "Gigantomastia induced by bucillamine". Annals of Plastic Surgery. 49 (2): 193–195. doi:10.1097/00000637-200208000-00013. PMID 12187348. Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone. It is rare for breast hypertrophy to be induced by drugs. In particular, gigantomastia has been reported to be induced by only two drugs: D-penicillamine and the antibiotic neothetazone. In 1970, drug-induced gigantomastia was reported for the first time by Scott.4 It was induced by the antibiotic Neothetazone.
  8. Dancey A, Khan M, Dawson J, Peart F (2008). "Gigantomastia--a classification and review of the literature". Journal of Plastic, Reconstructive & Aesthetic Surgery. 61 (5): 493–502. doi:10.1016/j.bjps.2007.10.041. PMID 18054304.
  9. Khan A, Agarwal R (April 2012). "Isoniazid related gynecomastia: Description of a case and systematic review of literature". Lung India. 29 (2): 189–191. doi:10.4103/0970-2113.95343. PMC 3354502. PMID 22628943.
Antimycobacterials, including tuberculosis treatment and leprostatic agents (J04)
Nucleic acid inhibitor
Rifamycins/
RNA polymerase inhibitor
Antifolates/DSI
ASA
Topoisomerase inhibitors/
quinolones
Protein synthesis inhibitor
Aminoglycosides
Oxazolidone
Polypeptide antibiotics
Cell envelope antibiotic
Peptidoglycan layer
Arabinogalactan layer
Mycolic acid layer
Other/unknown
Combinations
Antibacterials active on the cell wall and envelope (J01C-J01D)
β-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Penicillins (Penams)
Narrow
spectrum
β-lactamase sensitive
(1st generation)
β-lactamase resistant
(2nd generation)
Extended
spectrum
Aminopenicillins (3rd generation)
Carboxypenicillins (4th generation)
Ureidopenicillins (4th generation)
Other
Carbapenems / Penems
Cephems
Cephalosporins
Cephamycins
Carbacephems
1st generation
2nd generation
3rd generation
4th generation
5th generation
Siderophore
Veterinary
Monobactams
β-lactamase inhibitors
Combinations
Polypeptides
Lipopeptides
Other
  • Inhibits PG elongation and crosslinking: Ramoplanin
Intracellular
Other
Hydrazines


Stub icon

This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: